Journal
ANTI-CANCER DRUGS
Volume 30, Issue 10, Pages 1067-1070Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CAD.0000000000000837
Keywords
hyperprogression; lung cancer; radioresistance; tezolizumab
Categories
Funding
- Pla Estrategic de Recerca i Innovacio en Salut (PERIS) 2016-2020 de la Generalitat de Catalunya [SLT006/17/114]
- Spanish Ministry of Science and Innovation [SAF2016-80639-P]
- Fundacio Oncolliga Girona (Lliga Catalana d'ajuda al Malalt de Cancer, Girona)
Ask authors/readers for more resources
Immune checkpoint inhibitors (ICIs) represent a new standard of care for patients with advanced nonsmall cell lung cancer, improving overall survival compared with standard chemotherapy. However, a new pattern of response to ICIs characterized by accelerated tumor growth has been recently described, termed hyperprogressive disease (HPD). We report the case of a 73-year-old patient with advanced lung adenocarcinoma who developed HPD following treatment with a unique dose of atezolizumab for a skin metastasis that was refractory to chemotherapy and radiotherapy. Potential clinical biomarkers related to HPD to ICIs are reviewed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
